



US government (USG) investment in global health R&D has delivered

\$24.3 million

to New Mexico research institutions*

250+ new jobs

for New Mexico†

New Mexico's top global health R&D institutions by USG funding*

ORGANIZATION	FUNDING
University of New Mexico	\$18.4 million
Los Alamos Scientific Laboratory	\$4.9 million
The National Center for Genome Resources	\$497 thousand
Santa Fe Institute	\$362 thousand
The Lovelace Respiratory Research Institute	\$49 thousand

Neglected diseases in New Mexico‡

HIV diagnoses	1,257
Tuberculosis cases	432
West Nile cases	174
Malaria cases	18
Dengue cases	11

New Mexico industry in global health R&D


- Agilvax:** Albuquerque
- Creative LIBS Solution:** Bernalillo
- Mesa Biotech:** Santa Fe
- VisionQuest Biomedical:** Albuquerque

Global health R&D at work in the Land of Enchantment



University of New Mexico researchers have developed a rapid breath test to detect tuberculosis and other lung diseases, such as pneumonia. The noninvasive, easy-to-use test offers results in 10 minutes without need for expensive laboratory equipment. The test is a major step forward in terms of speed and portability. It will enable doctors in low-resource settings to quickly detect lung infections and get patients on treatment. The technology has led to the creation of a company headquartered in Santa Fe which plans to commercialize the test, highlighting the economic returns of global health research.

New Mexico's top areas of global health R&D by USG funding*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES‡



89¢ of every dollar

the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K new US jobs

\$33 BILLION in US economic growth.

*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007-2015 and for Ebola and select viral hemorrhagic fevers from 2014-2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghtcoalition.org for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See www.ghtcoalition.org for additional details.

‡Centers for Disease Control and Prevention: HIV diagnoses 2008-2016, Tuberculosis cases 2008-2016, West Nile virus disease cases 2008-2016, Malaria cases 2008-2014, Dengue virus infection cases 2010-2016.

§ Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶ NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.